Pancreatic Cancer Research

ResearcherSamsung Medical CenterActive in the last 2 years

Young Suk Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8769-3556; OpenAlex author ID A5101437342. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2011: 3 papers · 2012: 4 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 18

  1. Prediabetes Remission and the Subsequent Risk of Pancreatic Cancer: A Nationwide Cohort Study. Co-author DOI 10.1016/j.amepre.2025.107979↗
  2. Parity and Risk of Pancreatic Cancer Among Premenopausal Women: A Nationwide Cohort Study. Co-author DOI 10.1016/j.mayocp.2026.05.020↗
  3. Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age… Co-author DOI 10.1200/jco-25-01169↗
  4. L-Ascorbic acid preferentially kills KRAS mutant pancreatic cancer cells through DNA damage. Co-author DOI 10.1038/s41598-025-07668-1↗
  5. Smoking Cessation and Pancreatic Cancer Risk in Individuals With Prediabetes and Diabetes: A Nationwide Cohort Study. Co-author DOI 10.6004/jnccn.2023.7060↗
  6. Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study. Co-author DOI 10.1016/j.ejca.2021.12.027↗
  7. Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer. Co-author DOI 10.1177/17588359211038478↗
  8. Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. Co-author DOI 10.1186/s12885-018-4995-0↗
  9. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gem… Co-author DOI 10.1007/s00280-017-3351-4↗
  10. Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. Co-author DOI 10.18632/oncotarget.17463↗
  11. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Last author DOI 10.1007/s00280-013-2328-1↗
  12. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/pmic.201200101↗
  13. A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysi… Co-author DOI 10.1007/s10637-011-9651-3↗
  14. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. Co-author DOI 10.1097/coc.0b013e31821a83d7↗
  15. Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine. Co-author DOI 10.2217/pgs.12.82↗
  16. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Co-author DOI 10.1016/s1470-2045(11)70004-3↗
  17. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Co-author DOI 10.1158/1535-7163.mct-11-0269↗
  18. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Co-author DOI 10.1159/000328449↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jung Yong Hong · 8 shared papers, 2014–2026 · strength 1.87
  2. Joon Oh Park · 12 shared papers, 2011–2026 · strength 1.69
  3. Kyungdo Han · 4 shared papers, 2022–2026 · strength 1.09
  4. Joo‐Hyun Park · 4 shared papers, 2022–2026 · strength 1.07
  5. Ho Yeong Lim · 7 shared papers, 2011–2026 · strength 0.84
  6. Seung Tae Kim · 5 shared papers, 2011–2025 · strength 0.53
  7. Kee‐Taek Jang · 5 shared papers, 2011–2025 · strength 0.40
  8. Ho Yeong Lim · 1 shared paper, 2026 · strength 0.36
  9. J Y Park · 1 shared paper, 2026 · strength 0.36
  10. Hye-Lim Jang · 2 shared papers, 2011–2025 · strength 0.29
  11. Jin Seok Heo · 3 shared papers, 2012–2021 · strength 0.22
  12. Seong Ho Choi · 4 shared papers, 2012–2017 · strength 0.15
  13. In Woong Han · 1 shared paper, 2021 · strength 0.13
  14. Sang Hyun Shin · 1 shared paper, 2021 · strength 0.13
  15. Soo‐Youn Lee · 3 shared papers, 2012–2017 · strength 0.11
  16. Do‐Youn Oh · 2 shared papers, 2012–2017 · strength 0.09
  17. Joon-Oh Park · 2 shared papers, 2012–2017 · strength 0.08
  18. Hyung‐Doo Park · 2 shared papers, 2012–2017 · strength 0.08
  19. Kwang Hyuck Lee · 2 shared papers, 2012–2017 · strength 0.08
  20. Jong Kyun Lee · 2 shared papers, 2012–2017 · strength 0.08
  21. Tatsuya Ioka · 2 shared papers, 2011–2017 · strength 0.08
  22. Junji Furuse · 2 shared papers, 2011–2017 · strength 0.08
  23. Takuji Okusaka · 2 shared papers, 2011–2017 · strength 0.08
  24. Dong Wook Choi · 2 shared papers, 2011–2017 · strength 0.08
  25. Jun Ho Yi · 3 shared papers, 2011–2012 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.